CD30-targeting drugs: cure for mastocytosis? - Wikidata - awgldk - TriplyDB

CD30-targeting drugs: cure for mastocytosis?

CD30-targeting drugs: cure for mastocytosis?

http://www.wikidata.org/entity/Q36406971

about

Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.

P2860

Q38848273-14B61710-988D-4F10-926E-9A32183F5DF8

P2860

CD30-targeting drugs: cure for mastocytosis?

http://www.wikidata.org/entity/Q36406971

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

CD30-targeting drugs: cure for mastocytosis?

@ast

CD30-targeting drugs: cure for mastocytosis?

@en

type

label

CD30-targeting drugs: cure for mastocytosis?

@ast

CD30-targeting drugs: cure for mastocytosis?

@en

prefLabel

CD30-targeting drugs: cure for mastocytosis?

@ast

CD30-targeting drugs: cure for mastocytosis?

@en

P1433

Q36406971-CE91D2E9-49E4-4FE2-8BA4-64442E739135

P1476

Q36406971-D11D43FD-BD0A-4F16-B216-376430044611

P2093

Q36406971-AAEAB9BA-D659-4EC9-A7E2-3433E1160604

P2860

Q36406971-3D43C2C1-9D72-48F3-B57D-661F53A5BC3F

Q36406971-46575BDF-ADE8-4C0F-8F02-F48597F43616

Q36406971-6B9BB1EF-36C4-4B96-9E77-E59F955A823E

Q36406971-73BF2CC1-EBB5-4EC2-9604-E2C91A364D63

Q36406971-A91161F2-A274-4952-9BCB-8FE8CF8CD7BF

Q36406971-C49A0EB7-5E6A-425B-B95F-9C7E30DFD240

Q36406971-CCF303FF-3C6E-4575-B929-2544187BEAD0

Q36406971-DD6E2E87-CCC2-49FB-B3F4-8F0F1B580144

Q36406971-ECA61B8E-2813-441B-934E-A419EA4618E5

Q36406971-FE2C8D62-F1B8-4864-BADA-4D6245014794

P304

Q36406971-9BDF08CA-10A5-487D-909F-8A1B5AE96721

P31

Q36406971-94CAF9D6-AA93-4A27-B056-5EE42CA5FC0F

P356

Q36406971-D37400C0-3AD3-47EE-8BF3-4C9A65859712

P407

Q36406971-48ECB572-2086-4DE6-9244-C303E1CA9D82

P433

Q36406971-3BAEB47A-9FA3-44A5-B613-FEBC6F90BB46

P478

Q36406971-ED7C8B80-C6D4-4FA1-A7D2-8B38104B8573

P577

Q36406971-44042A54-ABE3-4FF5-A100-3AE04DBF8C05

P5875

Q36406971-1FC0CB69-B840-4ED1-A6D9-FCA619CAF5FA

P698

Q36406971-A56FAE25-72ED-44B5-91E8-B45908AD4B7E

P932

Q36406971-450DDC82-6CD9-46C5-9BD8-99129AEA8465

P356

BLOOD-2015-11-678631

P1433

P1476

CD30-targeting drugs: cure for mastocytosis?

@en

P2093

Irina Maric

http://www.w3.org/2001/XMLSchema#string

P2860

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.

Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.

Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.

Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis.

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.

P304

2771-2773

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2015-11-678631

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

126

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

288058569

http://www.w3.org/2001/XMLSchema#string

P698

26705339

http://www.w3.org/2001/XMLSchema#string

P932

4692137

http://www.w3.org/2001/XMLSchema#string